Daycase Hip and Knee Arthroplasty in Møre and Romsdal Trial

Condition(s) studied

Investigational drug(s) / intervention(s)

Total Hip Arthroplasty: Total arthroplasty replacement of the hip through anterior or posterior approach. Cemented, hybrid, reverse hybrid or cementless implants. Patients with this procedure will receive Pericapsular Nerve Group Block (PENG) by an aneaesthesiologist.

Total Knee Arthroplasty: Total artrohplasty replacement of the knee with or without patella resurfacing, and with or without tourniquet. Cemented, hybrid, reverse hybrid or cementless implants. Patients with this procedure will receive a femoral triangle block and genicular nerve blocks by an anaesthesiologist.

Unicondylar knee artrhoplasty: Uniconcylar artrohplasty of the knee with or without tourniquet. Cemented, hybrid, reverse hybrid or cementless implants. Patients with this procedure will receive a femoral triangle block and genicular nerve blocks by an anaesthesiologist.

Study summary

The DART Study is a prospective, multicentre observational cohort study evaluating day-case pathways for patients undergoing primary total hip arthroplasty, total knee arthroplasty, or unicompartmental knee arthroplasty at three hospitals in Møre og Romsdal, Norway (Volda, Ålesund and SNR). All patients scheduled for these procedures will be screened for eligibility for same-day discharge using predefined clinical, functional, and logistical criteria.

The primary objective is to determine the proportion of patients who are discharged on the day of surgery. Secondary objectives are to assess recovery, pain, complications, emergency department visits, readmissions, reoperations, and mortality during the first 30 days after surgery. Patient-reported outcomes, including quality of recovery, joint-specific function, quality of life, pain, and awareness of the joint replacement, will be assessed before surgery and during follow-up for up to three months.

Clinical and patient-reported data will be collected prospectively. Outcomes for patients discharged on the day of surgery will be compared with those of patients who remain in hospital overnight or longer. The study aims to evaluate the feasibility, safety, and patient experience of implementing standardized day-case hip and knee arthroplasty pathways within routine clinical practice.

Eligibility

Primary outcome measure(s)

• Proportion of same day discharge — The primary outcome measure is measured at the day of surgery. If by any chance a patient is readmitted to hospital the day after surgery, this is counted as a readmission.
  The proportion of patients that are not dicharged at the day of surgery, but are admitted to the ward for som reason including complications, social factors , PONV, pain etc. It does also include the patients readmitted on the day of surgery.

Trial sites (3)

More Helse Møre og Romsdal HF trials in Norway

Other trials for the same condition